Table 3.
Antibiotic Susceptibility Pattern Among ESBLs and Non-ESBL Isolates Among KTP and Control Group
| Antimicrobial Category | Antibiotics | ESBL-Positive Isolates | p-value | ESBL-Negative Isolates | p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KTP | Control Group | KTP | Control-Group | ||||||||
| R | S | R | S | R | S | R | S | ||||
| Beta-lactams | Amoxicillin/clavulanic | 7 (35) | 10 (50) | 7 (46.7) | 7 (46.7) | 0.6 | 8 (30.8) | 18 (69.2) | 8 (16) | 40 (80) | 0.32 |
| Piperacillin-tazobactam | 6 (30) | 14 (70) | 3 (20) | 12 (80) | 0.39 | 0 | 26 (100) | 4 (8) | 45 (90) | 0.25 | |
| Cefoxitin | 7 (35) | 13 (65) | 6 (40) | 9 (60) | 0.76 | 3 (11.5) | 23 (88.5) | 9 (18) | 41 (82) | 0.35 | |
| Ceftazidim | 20 (100) | 0 | 15 (100) | 0 | - | 3 (11.5) | 23 (885) | 7 (14) | 43 (86) | 0.53 | |
| Cefixim | 15 (75) | 5 (25) | 13 (86.7) | 2 (13.3) | 0.39 | 12 (46.2) | 14 (53.8) | 9 (18) | 40 (80) | 0.02 | |
| Cefepime | 9 (45) | 6 (30) | 2 (13.3) | 12 (80) | 0.14 | 1 (3.8) | 23 (88.5) | 5 (10) | 45 (90) | 0.09 | |
| Carbapenem | Imipenem | 0 | 20 (100) | 0 | 15 (100) | - | 0 | 26 (100) | 0 | 26 (100) | 0.2 |
| Meropenem | 0 | 20 (100) | 0 | 15 (100) | - | 0 | 26 (100) | 0 | 26 (100) | 0.2 | |
| Sulfonamides | Trimethoprim/sulfamethoxazole | 17 (85) | 3 (15) | 9 (60) | 6 (40) | 0.1 | 22 (84.6) | 4 (15.4) | 21 (42) | 28 (56) | 0.002 |
| Quinolones | Ciprofloxacin | 16 (80) | 4 (20) | 10 (66.7) | 5 (33.3) | 0.3 | 9 (34.6) | 16 (61.5) | 14 (28) | 35 (70) | 0.7 |
| Ofloxacin | 16 (80) | 4 (20) | 12 (80) | 3 (20) | 1.00 | 8 (30.8) | 18 (69.2) | 19 (38) | 30 (60) | 0.6 | |
| Nalidixic acid | 18 (90) | 2 (10) | 12 (80) | 2 (13.3) | 0.46 | 18 (69.2) | 8 (30.8) | 26 (52) | 21 (42) | 0.22 | |
| Norfloxacin | 16 (80) | 4(40) | 10 (66.7) | 5 (33.3) | 0.3 | 10 (38.5) | 16 (61.5) | 13 (26) | 37 (74) | 0.26 | |
| Nitrofurans | Nitrofurantoin | 3 (15) | 15 (75) | 0 | 14 (93.3) | 0.25 | 8 (30.8) | 18 (69.2) | 6 (12) | 44 (88) | 0.063 |
| Aminoglycosides | Gentamicin | 10 (50) | 10 (50) | 6 (40) | 9 (60) | 0.5 | 5 (19.2) | 21 (80.8) | 5 (10) | 45 (90) | 0.29 |
| Amikacin | 0 | 20 (100) | 0 | 15 (100) | - | 0 | 26 (100) | 2 (4) | 48 (96) | 0.3 | |